NYC’s Coronado Biosciences Plans Two Drug Trials, Wall Street Debut, and Boston Move
(Page 2 of 2)
remove NK cells from family members of AML patients, activate the cells in a test tube, and then infuse them back into the patient. In a trial with seven patients at University College London Business, which developed the molecule, remission times were lengthened and patients suffered few side effects, Sandage says. Coronado plans to file an IND early next year to study the drug in AML. The treatment has also shown early promise in breast, ovarian, and prostate cancer, as well as in multiple myeloma, he says.
The parasite treatment, CNDO-201, offers a different approach to modulating the immune system. The treatment was inspired by the “hygiene hypothesis”—an observation made by some academics that the incidence of autoimmune diseases such as Crohn’s has increased along with the cleanliness of society. Some experts believe that the lack of exposure to parasites may actually pre-dispose humans to inflammatory diseases. That’s because parasites similar to the pig worm that Coronado is studying actually regulate cell mechanisms that prevent excessive T-cell activation—one of the major causes of autoimmune disorders.
The idea is to give patients a dosage of eggs from the pig parasite every two weeks or so. “Because humans aren’t the right host, the worms can’t colonize,” Sandage explains. “The eggs stay there a couple of weeks and then dissolve.” But with regular dosing, the eggs seem to spark a positive immune response: In small trials in inflammatory bowel disease, upwards of 70 percent of patients achieved total remissions. If the FDA accepts Coronado’s IND, the company will start a trial in Crohn’s early next year, Sandage says.
Coronado is just the type of biotech startup that New York legislators would love to keep in the city, since life sciences is one of the industries that Mayor Michael Bloomberg has tapped as a major source of growth going forward. But Sandage says moving to Boston was a matter of logistics. Coronado’s chairman, Glenn Cooper, is based there, as is scientific co-founder Joel Weinstock, who did the original work on CNDO-201 and is now chief of the division of gastroenterology/hepatology at Tufts New England Medical Center.
Sandage and Cooper worked together for many years at Indevus, a Lexington, MA-based company that was bought by Endo Pharmaceuticals (NASDAQ: ENDP) in 2009. Sandage had moved to St. Louis to run Covidien’s oncology division when Cooper approached him to run Coronado. Sandage says he plans to commute to Boston for a while before he decides whether to move back. In the meantime, the company is preparing to move to office space that it leased in Burlington.
Despite the commuting requirement, Sandage says he didn’t need much convincing to join Coronado. “The projects are just so fascinating,” he says. “NKs are considered by oncologists to be the holy grail. You’re activating your own innate immune system to attack cancer cells. You can’t get more fundamental than that.”
As for those worms, Sandage says, “There are a hundred autoimmune diseases, and we can have our pick as to which ones we pursue. You don’t get many chances like this in a career. It was a pretty easy sell.”